Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:HRMY NASDAQ:HRTX NASDAQ:PRLD NASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.19-3.8%$3.09$1.05▼$3.97$358.54M2589,498 shs127,634 shsHRMYHarmony Biosciences$32.23-0.5%$35.65$26.47▼$41.61$1.86B0.84659,749 shs227,078 shsHRTXHeron Therapeutics$1.25-1.2%$1.63$1.04▼$2.68$228.23M1.221.66 million shs525,570 shsPRLDPrelude Therapeutics$1.14+0.9%$0.98$0.61▼$2.84$64.52M1.24191,538 shs57,017 shsSUPNSupernus Pharmaceuticals$44.15-2.9%$39.42$29.16▼$46.78$2.47B0.79634,528 shs212,700 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%-6.23%+5.41%-1.90%+6.77%HRMYHarmony Biosciences0.00%-10.00%-12.15%-1.55%-16.76%HRTXHeron Therapeutics0.00%-3.82%-5.26%-37.93%-32.62%PRLDPrelude Therapeutics0.00%-8.13%+29.89%+16.03%-59.21%SUPNSupernus Pharmaceuticals0.00%-1.17%+6.49%+40.01%+46.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.19-3.8%$3.09$1.05▼$3.97$358.54M2589,498 shs127,634 shsHRMYHarmony Biosciences$32.23-0.5%$35.65$26.47▼$41.61$1.86B0.84659,749 shs227,078 shsHRTXHeron Therapeutics$1.25-1.2%$1.63$1.04▼$2.68$228.23M1.221.66 million shs525,570 shsPRLDPrelude Therapeutics$1.14+0.9%$0.98$0.61▼$2.84$64.52M1.24191,538 shs57,017 shsSUPNSupernus Pharmaceuticals$44.15-2.9%$39.42$29.16▼$46.78$2.47B0.79634,528 shs212,700 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%-6.23%+5.41%-1.90%+6.77%HRMYHarmony Biosciences0.00%-10.00%-12.15%-1.55%-16.76%HRTXHeron Therapeutics0.00%-3.82%-5.26%-37.93%-32.62%PRLDPrelude Therapeutics0.00%-8.13%+29.89%+16.03%-59.21%SUPNSupernus Pharmaceuticals0.00%-1.17%+6.49%+40.01%+46.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75143.33% UpsideHRMYHarmony Biosciences 3.00Buy$51.0058.26% UpsideHRTXHeron Therapeutics 2.33Hold$4.50261.45% UpsidePRLDPrelude Therapeutics 3.00Buy$4.00250.88% UpsideSUPNSupernus Pharmaceuticals 2.50Moderate Buy$43.00-2.59% DownsideCurrent Analyst Ratings BreakdownLatest HRTX, SUPN, PRLD, ADCT, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025SUPNSupernus PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $40.008/19/2025SUPNSupernus PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/18/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$4.00 ➝ $3.008/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/6/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $46.007/30/2025SUPNSupernus PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$42.007/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.007/10/2025HRMYHarmony BiosciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $55.007/10/2025HRMYHarmony BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$33.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M5.06N/AN/A($2.10) per share-1.52HRMYHarmony Biosciences$714.73M2.59$2.93 per share10.99$11.56 per share2.79HRTXHeron Therapeutics$149.69M1.52N/AN/A($0.22) per share-5.66PRLDPrelude Therapeutics$7M9.22N/AN/A$2.39 per share0.48SUPNSupernus Pharmaceuticals$665.13M3.72$4.05 per share10.90$18.76 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)HRMYHarmony Biosciences$145.49M$3.1010.4110.360.3823.44%26.34%17.71%11/4/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)PRLDPrelude Therapeutics-$127.17M-$1.64N/AN/AN/AN/A-106.50%-79.07%11/5/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1538.3530.66N/A9.70%14.22%10.82%11/3/2025 (Estimated)Latest HRTX, SUPN, PRLD, ADCT, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PRLDPrelude Therapeutics-$0.45-$0.41+$0.04-$0.41N/AN/A8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 million8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66HRMYHarmony Biosciences0.203.843.80HRTXHeron TherapeuticsN/A0.820.53PRLDPrelude TherapeuticsN/A3.683.68SUPNSupernus PharmaceuticalsN/A2.582.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%HRMYHarmony Biosciences86.23%HRTXHeron Therapeutics80.01%PRLDPrelude Therapeutics79.72%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%HRMYHarmony Biosciences23.60%HRTXHeron Therapeutics5.86%PRLDPrelude Therapeutics63.90%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionablePRLDPrelude Therapeutics12056.60 million20.43 millionOptionableSUPNSupernus Pharmaceuticals58056.07 million51.14 millionOptionableHRTX, SUPN, PRLD, ADCT, and HRMY HeadlinesRecent News About These CompaniesRhumbline Advisers Sells 7,121 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 15 at 3:45 AM | marketbeat.comVillanova Investment Management Co LLC Has $641,000 Stock Position in Supernus Pharmaceuticals, Inc. $SUPNSeptember 13 at 6:33 AM | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Shares Sold by Great Lakes Advisors LLCSeptember 12 at 5:37 AM | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $292,645.38 in StockSeptember 11, 2025 | marketbeat.comAxiom Investors LLC DE Sells 15,521 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 11, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 55,578 SharesSeptember 10, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - Here's WhySeptember 10, 2025 | marketbeat.comCEO’s Major Stock Sale Shakes Up Supernus PharmaceuticalsSeptember 9, 2025 | tipranks.comCan Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?September 9, 2025 | finance.yahoo.comSupernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $2,557,143.78 in StockSeptember 9, 2025 | insidertrades.comUnpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals StocksSeptember 8, 2025 | finance.yahoo.comSupernus Pharmaceuticals, Inc. $SUPN Stock Position Cut by PDT Partners LLCSeptember 6, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Stock Position Raised by Cubist Systematic Strategies LLCSeptember 6, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 52-Week High - What's Next?September 4, 2025 | marketbeat.comTrexquant Investment LP Has $4.73 Million Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 3, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Armistice Capital LLCSeptember 2, 2025 | marketbeat.comNorthern Trust Corp Cuts Stock Holdings in Supernus Pharmaceuticals, Inc. $SUPNSeptember 2, 2025 | marketbeat.com2 Healthcare Stocks on Our Watchlist and 1 We AvoidSeptember 1, 2025 | uk.finance.yahoo.comAshford Capital Management Inc. Purchases 20,781 Shares of Supernus Pharmaceuticals, Inc. $SUPNSeptember 1, 2025 | marketbeat.comPiper Sandler Raises Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target to $40.00August 31, 2025 | marketbeat.comHsbc Holdings PLC Sells 180,627 Shares of Supernus Pharmaceuticals, Inc. $SUPNAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRTX, SUPN, PRLD, ADCT, and HRMY Company DescriptionsADC Therapeutics NYSE:ADCT$3.18 -0.13 (-3.78%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Harmony Biosciences NASDAQ:HRMY$32.22 -0.17 (-0.51%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Heron Therapeutics NASDAQ:HRTX$1.25 -0.02 (-1.19%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Prelude Therapeutics NASDAQ:PRLD$1.14 +0.01 (+0.88%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Supernus Pharmaceuticals NASDAQ:SUPN$44.14 -1.32 (-2.89%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
